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Abstract: Angiogenesis is largely an adaptive response to tissue hypoxia, which occurs in a wide variety of sit-
uations. Interestingly, the extent of hypoxia-induces angiogenesis in the cardiac muscle of children diagnosed 
with congenital cyanotic heart defects is not well established. Thus, the aim of this study was to 1) estimate the 
cardiac muscle microvessel density (MVD) in children diagnosed with cyanotic (study group) and non-cyanotic 
(control group) heart defects and to 2) evaluate the prognostic significance of MVD value in the development 
of ventricular dysfunction in the postoperative period. The study group included 42 children diagnosed with 
cyanotic heart defects. The control group comprised 33 patients with a diagnosis of non-cyanotic heart failure. 
The collected tissue included cardiac muscle sections from the right atrium and interventricular or interatrial 
wall during surgical correction of the defect. Immunocytochemistry with monoclonal mouse anti-human anti-
bodies against CD31, CD34 and CD105 was employed to estimate the MVD value. The mean cardiac muscle 
MVD, defined by CD34 expression, was 596.7 ± 32.6 microvessels per 1 mm2 in the study group, which was not 
significantly different from the mean MVD in the control group (461.2 ± 30.5). Interestingly, in non-cyanotic 
heart defects, an inner area of subendocardial meshwork was estimated to have 75.3 ± 7.0 microvessels per 
1 mm2, compared to 92.8 ± 10.9 microvessels per 1 mm2 (p = 0.0082) in patients with cyanotic heart defects. 
No significant correlations between MVD value and ventricular dysfunction were found. Cyanotic heart defects 
resulting in chronic hypoxia might provoke angiogenesis in the subendocardial meshwork of the heart wall. The 
process seems to be independent of the type of cyanotic heart disease and most likely takes place during antenatal 
development. A ventricular dysfunction observed in some cases of cyanotic heart defects could not be predicted 
by the estimation of MVD. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 4, 278–285)
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Introduction
Anatomic abnormalities in cyanotic congenital heart 
defects result in decreased pulmonary blood flow and 
lead to systemic hypoxia [1]. Moreover, patients with 
these types of defects frequently develop ventricular 
dysfunction in the postoperative period [2]. However, 
the histological basis of these functional alterations 
is not clear. Individual investigations have reported 
significant differences in cardiomyocyte diameter, 
amount of collagen fibers and microvessel density 
(MVD) in different regions of the myocardium in 
patients with Fallot’s tetralogy [2].
Chronic hypoxia provokes the systemic modification 
of internal organ structure and function [1]. Angioge-
nesis is largely an adaptive response to tissue hypoxia, 
which occurs in a wide variety of situations [3, 4]. Intere-
stingly, the extent of hypoxia-induces angiogenesis in the 
cardiac muscle of children diagnosed with congenital 
cyanotic heart defects is not yet well established [2, 5].
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One of the most sensitive histological parameters 
that reflects the extent of anoxia involves MVD, which 
can be defined by the relative expression levels of 
CD31, CD34 and/or CD105 [6]. CD31 is expressed on 
the surface of the continuous endothelium of mature 
blood vessels. It is a 130 kDa transmembrane protein 
with an important role as an adhesion molecule for en-
dothelial-endothelial cell interactions and leukocyte
-endothelial cell interactions [7, 8]. CD34 is expressed 
on the surface of most bone marrow hematopoietic 
cells and mature endothelial cells. Interestingly, it 
is highly expressed during the preliminary stages of 
endothelial progenitor cell development and in later 
stages of blood vessel development [7]. Therefore, the 
estimation of CD34 expression allows for the evalu-
ation of mature and developing blood vessels. Quanti-
fication of the combined CD31 and CD34 expression 
or the calculation of the CD34/CD31 ratio provides 
a determination of the fraction and location of blood 
vessels with a relatively higher angiogenic potential. 
These parameters allow for an indirect estimation 
of relative tissue anoxia during morphogenesis and 
angiogenesis [9]. Additionally, the ratio of CD105 
(endoglin) to CD31 is widely used as an indicator of 
angiogenesis [10]. CD105 is a proliferation-associated 
and hypoxia-inducible factor abundantly expressed 
in activated endothelial cells and is a receptor for 
transforming growth factor [11, 12]. 
In line with the above, the aim of the present re-
search was to 1) estimate cardiac muscle microvessel 
density in children diagnosed with cyanotic (study 
group) and non-cyanotic (control group) heart defects 
by means of immunohistochemistry and morphometry 
and to 2) evaluate the prognostic significance of MVD 
value in the evolution of ventricular dysfunction in the 
postoperative period. 
Material and methods
Patients. The study group included 42 children diagnosed 
with cyanotic heart defects (23 boys and 19 girls; mean age 
3.4 ± 2.1 years). The control group comprised 33 patients 
diagnosed with a non-cyanotic heart defect (19 boys and 
14 girls; mean age 8.2 ± 3.7 years). 
The cyanotic heart defects included tetralogy of Fallot 
(n = 8), Ebstein’s anomaly (n = 2), atresia of the pulmonary 
valve (n = 9), tricuspid atresia (n = 13) and transposition of 
the great vessels (n = 10). The non-cyanotic heart defects 
included ventricular septal defect (n = 9), atrial septal defect 
(n = 14), patent ductus arteriosus (n = 8) and coarctation 
of the aorta (n = 2).
All of the patients were surgically treated in the Depart-
ment of Pediatric Cardiac Surgery, University of Medical 
Sciences in Poznan, Poland between March 15th, 2010 and 
September 15th, 2011. The research protocol was approved 
by the Ethics Committee of Poznan University of Medical 
Sciences, and the parents of all participants gave informed 
consent for the investigation. All of the analyses were per-
formed blind on coded samples. The patients’ preoperative 
data are summarized in Table 1.
Surgical procedure. The tissue examined originated from 
the cardiac interventricular or interatrial septum or from the 
atrial wall and was removed during the surgical correction of 
heart defects. Detailed information about the tissue origin in 
each group is presented in Table 1. One day before cardiac 
surgery, complete blood morphology was estimated for each 
patient, including C-reactive protein value and coagulation 
parameters. Following the anesthetization of the patient and 
opening of the thorax in a stereotypical manner, sutures were 
applied to the aorta and right atrium to couple the patient to 
extracorporeal circulation. Aortal cannula was introduced, 
and the opening was broadened to insert a cannula into the 
vena cava superior. A fragment of the right atrium wall was 
taken for the studies. During the heart defect correction sur-
gery, two or three fragments of interatrial or interventricular 
septum were taken for the studies. The excision of these 
fragments was medically necessary to apply the correcting 
patch and to fit it to cardiac structures [13]. 
The excised samples were fixed in Bouin’s solution at 
room temperature for 24 h and embedded in paraffin.
Immunohistochemistry. Briefly, deparaffinized 3–4 µm 
sections were pre-treated in a microwave (800 W, citrate 
buffer). To analyze CD31, CD34 and CD105 expression in 
cardiac biopsies, an indirect immunocytochemical procedure 
(the streptavidin-biotin complex method with the use of 
horseradish peroxidase) was performed using monoclonal 
mouse anti-human antibodies against CD31 (Dako, Copen-
hagen, Denmark; M00823, diluted 1:100), CD34 (Dako, 
M7165, diluted 1:100) and CD105 (Dako, M3257, diluted 
1:150). Following incubation with the primary antibody for 
24 h at 4°C, the specimens were treated for 1 h at room 
temperature with biotin-conjugated goat anti-mouse IgG 
(Sigma, Munich, Germany; diluted 1:300). Subsequently, the 
sections were incubated with an ABC reagent (Vectastain, 
Elite; Vector, Burlingame, CA, USA) for 45 min at room 
temperature. The activity of peroxidase was detected by tre-
ating the sections with 0.5% 3,3’-diaminobenzidine in Tris/ 
/HCl (pH = 7.6) containing 0.3% H2O2. Finally, the sections 
were counterstained with hematoxylin. Normal mouse IgG at 
the same concentrations as the primary antibodies (Dako, X 
0931, diluted 1:100) or phosphate buffer saline (PBS) were 
used as negative controls. 
Morphometric and statistical analyses. A sequence of 
5 serial preparations was quantified in all of the patients 
for expression of CD31, CD34 and CD105. Images were 
acquired using a high-resolution scanning technique (wor-
king magnification of 400 × with the autofocus function) 
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Table 1. Patients’ data (preoperative) 
Cyanotic heart defect (n = 42) Non-cyanotic heart defect (n = 33) p-value
Gender (male/female) 23/19 19/14 ns
Age (years) 3.4 ± 2.1 8.2 ± 3.7 p < 0.01
Diagnosis TOF (n = 8)
Ebstein’s anomaly (n = 2)
Pulmonary atresia (n = 9)
Tricuspid atresia (n = 13)
TGV (n = 10)
VSD (n = 9) 
ASD (n = 14)
PDA (n = 8)
Aortic coarctation (n = 2)
BMI [kg/m2] 17.2 ± 1.8 18.5 ± 2.2 ns
Preoperative O2 satu-
ration
84.6 ± 3.3 96.5 ± 2.8 p < 0.01
Tissue origin obtained 
during surgery
Interatrial septum (n = 6)
Interventricular septum (n = 14)
Atrial wall (n = 22)
Interatrial septum (n = 14)
Interventricular septum (n = 9)
Atrial wall (n = 10)
Diastolic interatrial wall 
thickness [mm]
TOF (0.8 ± 0,2)
Ebstein’s anomaly (0.7 ± 0.2)
Pulmonary atresia (0.7 ± 0.2)
Tricuspid atresia (0.8 ± 0.1)
TGV (0.9 ± 0.3)
VSD (0.8 ± 0.2) 
ASD (0.6 ± 0.2)
PDA (0.7 ± 0.1)
Aortic coarctation (0.8 ± 0.2)
ns
Diastolic Interventricu-
lar wall thickness [mm]
TOF (0.9 ± 0.2)
Ebstein’s anomaly (1.0 ± 0.2)
Pulmonary atresia (1.0 ± 0.3)
Tricuspid atresia (0.9 ± 0.3)
TGV (1.3 ± 0.3)
VSD (0.9 ± 0.1) 
ASD (0.9 ± 0.2)
PDA (1.0 ± 0.2)
Aortic coarctation (1.2 ± 0.4)
ns
ns — not significant; TOF — tetralogy of Fallot; TGV — transposition of the great vessels; VSD — ventricular septal defect; ASD — atrial septal 
defect; PDA — patent ductus arteriosus
and the MiraxMidi microscope scanner (Carl Zeiss, Poznan, 
Poland). The resulting graphic file, encompassing the entire 
preparation surface, was subjected to morphologic and mor-
phometric analysis using MiraxViewer software (Carl Zeiss).
To determine MVD, three regions of each preparation 
with the highest number of blood vessels were subjected to 
analysis (‘hot-spots’ technique), and the mean blood vessel 
density (number of blood vessels per 1 mm2) was calculated, 
dividing the average number of blood vessels in ‘hot-spots’ 
by the area of the field [14]. This procedure was applied 
separately for CD31, CD34 and CD105. Finally, the CD34/ 
/CD31 and CD105/CD31 angiogenic indices were calculated 
to optimize the activated blood vessel ratio, which could 
be then used in the evaluation of prognostic significance 
in children diagnosed with cyanotic heart defects. In the 
subsequent stage of the studies, MVD values were deter-
mined in regions of the sample that are most susceptible 
to the effects of chronic anoxia (e.g., peripheral portions of 
the preparation in the vicinity of the atrial and ventricular 
lumen). Such an analysis, however, was not based on the 
‘hot-spots’ approach, and all blood vessel cross-sections 
were scored (with expression of CD31, CD34 and CD105).
Continuous or interval-related variables were expressed 
as the means ± SD. Comparisons of continuous variables 
between groups were performed using Student’s t-test. 
Comparisons of discrete variables between groups were per-
formed using the Mann-Whitney test. Alpha adjustment for 
all of the multiple comparisons used Bonferroni correction. 
Independent risk factors for ventricular dysfunction and 
the relationship between age or gender and MVD within 
each analyzed group were determined using Fisher’s exact 
test. The cut-off points for age were arbitrarily estimated at 
18 months and 4 years for cyanotic and non-cyanotic defects, 
respectively. For MVD, an arbitrary cut-off point was set 
at 400 microvessels per 1 mm2 in all of the patient samples. 
P < 0.05 was considered statistically significant.
Results
Clinical observation
The post-operative observation protocol varied de-
pending on the type of complications. Twenty-eight 
children from the study group and 27 patients from 
the control group demonstrated no significant com-
plications and were released within 14 days after the 
surgery. Six children in the study group and 2 subjects 
from the control group developed a transient left 
ventricular dysfunction (characterized by tachyp-
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nea, pulmonary edema and cyanosis) and required 
a subsequent surgery. The ejection fraction (EF) of 
patients suffering from this complication, estimated 
by echocardiography, was > 30%. Four children in 
the study group and two patients in the control group 
developed pneumonia. EF in these study participants 
was between 30 and 55%. Sepsis or severe wound 
infection were diagnosed in two children from the 
study group and a single child in the control group. 
These patients required a longer hospital stay. Finally, 
a single patient with a non-cyanotic heart defect and 
two children with cyanotic heart disease died in the 
period between 1 and 7 days after surgery (Table 2). 
Evaluation of MVD value in cardiac  
muscle biopsies
We compared the MVD between cyanotic and non-cy-
anotic patients by quantifying CD31, CD34 or CD105 
expression. In the study group, the mean MVD (de-
termined by ‘hot-spots’ technique) assessed by CD31 
expression was 405.8 ± 26.9 microvessels per 1 mm2. 
The mean MVD determined by CD34 expression was 
596.7 ± 32.6 microvessels per 1 mm2 (p = 0.01) in the 
study group. The number of CD105-positive blood 
vessels in 1 mm2 of cardiac muscle biopsies of patients 
in the study group ranged from 483.6 and 529.2, and 
an average MVD defined by CD105 expression was 
505.3 ± 25.6 microvessels per 1 mm2 (p = 0.03 compared 
to CD31 and CD34). Analogously, the control group 
MVD value, determined by CD31 or CD34 expres-
sion, was 315.6 ± 23.6 and 461.2 ± 30.5 microvessels 
per 1 mm2 (p < 0.001), respectively, and 388.3 ± 19.2 
microvessels per 1 mm2 when defined by CD105 
expression (p = 0.04 compared to CD31 and CD34). 
An average CD34/CD31 index in cardiac muscle 
biopsies from the study group was 1.47, and the mean 
CD105/CD31 ratio was 1.25 (not significant). In the 
control group, the CD34/CD31 index was 1.46, and 
the CD105/CD31 ratio was 1.23 (not significant). The 
mean cardiac microvessel density in cyanotic patients 
was not statistically significantly different than the 
mean MVD in non-cyanotic patients (Figure 1).
We next examined a subendocardial area of the 
cardiac wall (known for its constitutive vessel desti-
tution) for MVD value. We found that the MVD 
value defined by CD31 expression was 61.9 ± 13.3 
microvessels per 1 mm2 in the control group, while 
CD34 and CD105 expressions estimated the MVD to 
be 75.3 ± 7.0 and 72.4 ± 5.6, respectively (not signi-
ficant). In contrast, the CD31 MVD value 71.1 ± 9.5 
microvessels per 1 mm2 in the control group, whi-
le the CD34 and CD105 MVD calculations were 
significantly higher at 92.8 ± 10.9 and 89.9 ± 7.3, 
respectively (p = 0.005, CD31 vs. CD34 expression; 
p = 0.008, study group vs. control group). These fin-
dings are illustrated in Table 3 and Figures 2 and 3.
Differences in CD31, CD34 and CD105 expression 
and MVD values, CD34/CD31 and CD105/CD31 
angiogenic ratios did not correlate with age or gender 
of patients or early treatment failures, as determined 
by clinical observation. Moreover, there was no signi-
ficant difference in MVD value within the studied 
groups when comparing different tissues (atrial wall, 
interatrial septum or interventricular septum).
Discussion
The subendocardial meshwork (area) is a small region 
(restricted to 150–200 µm) in the cardiac wall of the 
left ventricle, ventricular septum, or papillary muscles, 
which is the farthest from the heart’s blood supply and 
is more susceptible to systemic hypoxia [15]. Oxygen 
and nutrients are usually supplied indirectly from the 
blood stream in the ventricle. Subendocardial infarc-
tions in adults are thought to be a result of locally 
decreased blood supply, possibly from a narrowing 
of the coronary arteries [16, 17]. 
In the present study, the mean MVD value in the 
subendocardial area was significantly larger in pa-
tients diagnosed with cyanotic heart defects compared 
to non-cyanotic study participants. The mean age of 
patients with cyanotic defects was significantly lower 
compared to non-cyanotic patients. Furthermore, the 
non-cyanotic group of children underwent a cardiac 
surgery at a later age, due to less severe heart disease. 
Interestingly, the MVD value in the cardiac wall, with 
the exception of the subendocardial meshwork, was 
comparable between cyanotic and non-cyanotic heart 
diseases. These data may indicate systemic hypoxia in 
cyanotic hearts even during prenatal development, 
Table 2. Patients’ data (postoperative) 
Cyanotic 
heart 
defect  
(n = 42)
Non- 
-cyanotic 
heart 
defect  
(n = 33)
p-value
No complications (male//
female)
13/15 15/12 ns
Transient left ventricular 
dysfunction (male/female)
3/3 1/1 p < 0.01
Pneumonia (male/female) 3/1 1/1 p < 0.01
Sepsis (male/female) 2/0 1/0 ns
Death
(male/female)
2/0 1/0 ns
ns — not significant 
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Figure 1. Demonstration of microvessels density in cardiac muscle biopsies of children with congenital heart defects. Sections 
were stained by immunohistochemistry to show the MVD defined by CD31 (A and C) and CD34 (B and D) expression. A and B 
were obtained from a representative child diagnosed with cyanotic heart defect (transposition of the great vessels). C and D were 
obtained from a patient with non-cyanotic heart disease (atrial septal defect type II). SM = subendocardial meshwork. CD34 
expression seems to be a more valuable marker than CD31 for the estimation of MVD in cardiac biopsies. Scale bar = 150 µm
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Table 3. Morphometric evaluation of vessels in the suben-
docardial tissue of children with cyanotic and non-cyanotic 
heart disease
Cyanotic 
heart defect 
(n = 42)
Non-cyanotic 
heart defect 
(n = 33)
p-value
Microvessel diameter 
[µm]
13 ± 5.6 12 ±4.1 ns
MVD CD31 [ves-
sels/1 mm2]
405.8 ± 26.9 315.6 ± 23.6 ns
MVD CD34 [ves-
sels/1 mm2]
596.7 ± 32.6* 461.2 ± 30.5## p < 0.05
MVD CD105 [ves-
sels/1 mm2]
505.3 ± 
25.6*
388.3 ± 19.2# p < 0.05
CD34/CD31 1.47 1.46 ns
CD105/CD31 1.25 1.23 ns
Subendocardial MVD 
CD31 [vessels/1 mm2]
71.1 ± 9.5 61.9 ± 13.3 ns
Subendocardial MVD 
CD34 [vessels/1 mm2]
92.8 ± 10.9 75.3 ± 7.0 p < 0.01
Subendocardial MVD 
CD105 [vessels/1 mm2]
89.9 ± 7.3 72.4 ± 5.6 p = 0.008
MVD CD31, –CD34 and –CD105 —microvessel density defined by the 
expression of CD31, CD34 and CD105, respectively; *p < 0.01 compared to 
‘cyanotic’ heart defect; #p < 0.001 compared to ‘non-cyanotic’ heart defect; 
CD34/CD31, angiogenic ratio defined as MVD CD34 to MVD CD31 ratio; 
CD105/CD31, angiogenic ratio defined as MVD CD105 to MVD CD31 ratio
and an increase in the formation of blood vessels in 
the area closest to the ventricular or atrial lumen of 
the heart. In non-cyanotic patients, this part of the 
cardiac wall was not occupied by an increased number 
of blood vessels, which might suggest that the age of 
the patients or the delayed time of surgery do not 
affect neovascularization. Interestingly, the diastolic 
thickness of the interatrial or interventricular wall in 
cyanotic or non-cyanotic children was not significantly 
different. The mean thickness values were reported 
in previous studies [18].
It must be emphasized that endothelial progenitor 
cells (EPCs) contain three types of cells [19], including 
early endothelial progenitor cells, recruited from stem 
cells of bone marrow stroma [20], and early and late 
endothelial progenitor cells, which circulate in the 
blood [21]. 
Early and late forms of circulating EPCs are 
characterized by the gradual decrease in CD133 
expression, with an increase in CD105, CD31 and 
von Willebrand’s factor expression [4]. Of note, late 
EPCs no longer express CD133, while the presence 
of CD34 is variable [21–23]. CD105 is a much more 
specific marker than leukocyte antigen CD34 and is 
a useful marker for activated endothelial cells. CD34 
is a common blood vessel marker for both mature and 
developing endothelial cells [10–12]. In this study, 
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Figure 2. Demonstration of microvessels density in subendocardial meshwork of children with congenital heart defects. 
Sections show the immunoreactivity of CD31 (A and C) and CD34 (B and D) in microvessels. A and B, transposition of 
the great vessels; C and D, non-cyanotic heart defects (atrial septal defect type II). A significantly higher number of ves-
sels was present in the subendocardial heart tissue in cyanotic heart diseases. CD34 staining was a more accurate marker 
for the determination of the MVD value. Scale bar = 150 µm; SM = subendocardial meshwork
we found that MVD estimations by CD34 or CD105 
expression did not significantly differ in cardiac musc-
le biopsies of the control and study groups. Moreover, 
the CD34/CD31 index was similar to the CD105/CD31 
ratio in both cyanotic and non-cyanotic heart defects. 
These results indicate that in cardiac muscle biopsies, 
the number of activated blood vessels (defined by 
expression of CD105) is similar to the number of all 
blood vessels (defined by means of CD34). Thus, just 
two markers, CD31 and CD34, may define the degree 
of endothelial maturity in a precise way.
The principal observation stemming from this 
study is linked to significant differences in the expres-
sion of CD31 and CD34 within the same sections of 
myocardium. This might indicate that CD31 does 
not represent a sufficiently good marker for the esti-
mation of MVD in cyanotic and non-cyanotic heart 
defects. Alternatively, CD31 and CD34 distributions 
are distinct. Subendocardial regions of cardiac 
sections contained a significantly higher number 
of CD34- and CD105-positive blood vessels in the 
study group compared to the control group of non-
cyanotic heart defects. This observation was surprising 
because CD31 expression alone could not detect the 
difference in MVD between the two groups of heart 
defect patients. These discrepancies may be due to the 
relatively small sample size and lack of prior research 
studies on the topic. 
The MVD values in cardiac muscle of children 
with congenital heart diseases reported in this study 
are one of the first results obtained for this group of 
diseases. Earlier studies focused primarily on myocar-
dial reconstruction during cardiac overload pathology. 
Rakusan et al. [24] found that the density of capillaries 
in hypertensive overload of the left cardiac ventricle 
was directly related to the severity of the defect. In 
adults, myocardial hypertrophy was found to result 
from compromised angiogenic compensation. 
Cardiac vessel density itself can be estimated by 
CD31 expression. Angio T cell factor was first used 
to demonstrate the vasculoprotective abilities and 
neoangiogenesis of CD31-positive blood vessels [24]. 
Kushner et al. [25] previously demonstrated that chan-
ges in subpopulations of CD31-positive cells decrease 
angiogenic potential and augment the probability of 
developing age-related circulatory diseases. Thus, 
MVD has been recognized as a prognostic factor for 
the adaptive tissue potential for anoxia [26]. 
In the case of congenital heart defects, we pro-
pose that CD34 expression is a good marker for the 
evaluation of MVD and may also be used as an index 
for anoxia in selected regions of myocardial samples. 
284 Paulina Jankowska et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2013
10.5603/FHC.2013.0038
www.fhc.viamedica.pl
Figure 3. Comparison of CD31, CD34 and CD105 expression on serial cardiac slides in cyanotic and non-cyanotic heart 
defects. A, C, E — atrial septal defect type II; B, D, F — Fallot’s tetralogy. Immunoreactivity of CD31 did not differ be-
tween non-cyanotic (A) and cyanotic (B) heart defects. Expression of CD34 was significantly higher compared to CD31, 
especially in the subendocardial meshwork (D). Immunoreactivity of CD105 was significantly higher compared to CD31 
and slightly lower compared to CD34 expression. Scale bar = 150 µm
A B
C D
E F
Non-cyanotic heart defect Cyanotic heart defect
CD31
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The observed post-surgery complications, inclu-
ding sepsis and pneumonia, need a separate attention. 
According to previous observations made by us and 
other research groups, all the other differences in both 
study groups were secondary to differences in age and 
immune system immaturity and incompetence.
In conclusion, cyanotic heart defects resulting in 
chronic hypoxia might exclusively provoke angiogene-
sis in the subendocardial meshwork of the heart wall. 
The angiogenic process is independent of the type 
of cyanotic heart disease and most likely takes place 
during antenatal development. A ventricular dysfunc-
tion observed in some cases of cyanotic heart defects 
could not be predicted by the estimation of MVD.
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